A new company will develop “next-generation mRNA” projects, amid another mRNA setback.
ApexOnco Front Page
Recent articles
Persevera is a bust, but Roche hasn’t given up on the front line.
With a slashed valuation the newly listed biotech heads for phase 3.
SGN-CEACAM5C carries the same antibody as the discontinued tusamitamab ravtansine.
Padcev has eaten into bladder expectations, while a Tukysa trial has also gone.
An actinium-based backup and Werner helicase inhibitor are notable absences.
First-in-human listings bring a bispecific and yet another in vivo Car-T.
But the Astra/Daiichi ADC stumbles in lung cancer.
